DiNAQOR AG is rated 3 out of 5 in the category biotechnology. Read and write reviews about DiNAQOR AG. DiNAQOR AG is a global gene therapy platform company focused on advancing novel solutions for patients suffering from heart disease. The company’s lead preclinical program, DiNA-001 is focused on the treatment of MYBPC3-linked cardiomyopathy. DiNAQOR is headquartered in Pfäffikon, Switzerland, with additional presence in London, England and Boston, Massachussetts USA.
Company size
1-10 employees
Headquarters
Pfäffikon, Zurich